Olema Oncology, Inc. has officially changed its corporate name from Olema Pharmaceuticals, Inc. The change, effective November 12, 2026, reflects the company’s commitment to oncology within the pharmaceutical preparations industry.

The name change was approved by the company’s Board of Directors and became effective at 4:01 p.m. Eastern Time on the same day. According to the filing, stockholder approval was not required to effect this change under Delaware General Corporation Law.

Olema Oncology, based in South San Francisco, focuses on developing therapies for cancer treatment. The rebranding aligns with its strategic goals and enhances its identity in the competitive landscape of oncology-focused pharmaceutical companies.

As part of its recent filings, Olema Oncology has also reported other events and financial disclosures, indicating ongoing activity and transparency in its operations. The company operates under the ticker symbol OLMA on the Nasdaq exchange.

Moving forward, Olema Oncology will continue to pursue its mission in oncology, and further updates on its progress and initiatives are anticipated in future filings.

Details of the Name Change

The name change to Olema Oncology, Inc. was formalized through the filing of the Eighth Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware. This filing underscores the company's strategic focus on oncology, which is a critical area of growth within the pharmaceutical industry.

The effective date of the name change was precisely at 4:01 p.m. Eastern Time on November 12, 2026. This timing reflects the company's proactive approach to aligning its corporate identity with its operational focus.

Corporate Structure and Compliance

Olema Oncology, Inc. is incorporated in Delaware and operates under the Central Index Key (CIK) number 0001750284. The company is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. This classification is indicative of its commitment to developing and providing innovative cancer therapies.

Moreover, the company maintains its fiscal year-end on December 31, consistent with standard practices for many corporations in its sector. This alignment allows for streamlined financial reporting and compliance with regulatory requirements.

Contact Information

For further inquiries, Olema Oncology can be reached at their business address: 365 Oyster Point Boulevard, Suite 400, South San Francisco, California, 94080. The company's contact number is (415) 651-3316, providing a direct line for stakeholders and interested parties.

Olema Oncology, Inc. continues to position itself as a key player in the oncology sector, with a clear focus on innovation and growth.